1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

 
• By Joseph Haas

A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.

woman in a laboratory microscope with microscope slide in hand.toned image.

Allergan PLC tried to put the most positive spin on it, but top-line two-year data from a Phase IIb study of its lead NASH candidate cenicriviroc has analysts wondering what’s the drug’s benefit will be if any. With Allergan revealing Sept. 22 that after two years of treatment, cenicriviroc (CVC) showed no meaningful difference compared to placebo in reducing fibrosis score in NASH patients, Credit Suisse went as far as removing potential revenue for the drug from its modeling.

The Dublin-domiciled specialty pharma claimed that the two-year data from CENTAUR testing CVC, a dual CCR2/CCR5 inhibitor, “supports continued development” of the drug in a Phase III trial initiated this past April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.